2-peptide research blend in one vial: BPC-157 + TB-500. Two-peptide tissue-repair blend — BPC-157 and TB-500 in a 1:1 ratio.
Also known as: Wolverine Stack · BPC-157 + TB-500 blend
A blend has one whole-vial purity, but the number that decides what you're holding is the net content of each component — an HPLC run resolves a separate peak for each. So we verify Wolverine component by component. Each links to its own compound page, where its full independent testing lives.
| Component | Typical mg | Role in the blend | Verified purity | |
|---|---|---|---|---|
| BPC-157 | varies | Local soft-tissue, tendon, and gut-lining repair | 99.3% · 784 tests | View testing → |
| TB-500 | varies | Cell migration, angiogenesis, systemic recovery | 99.4% · 350 tests | View testing → |
Composition varies by vendor. The components above are consistent across shops, but the milligrams and ratio are not — always dose by the individual component amounts printed on your vial, never by a generic “blend dose.”
A blend is the single hardest product to trust — the whole-vial purity tells you the material is clean, but not whether every peptide is present in the right amount. Two questions decide that, and both are answerable in a lab.
Mass spec (or a clean HPLC peak per compound) confirms each peptide is in the vial — not one short, not a cheaper substitute standing in for the expensive one.
Tested milligrams vs. labelled milligrams, per component. This is where blends fail quietly — one component underdosed to pad margin while the vial still “contains” everything.
Tests run on a Wolverine vial as sold — broken down per component. This is the data no shop and no competitor publishes.
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| BPC-157 | 10 mg | 9.931 mg | ✓ present | Within (-0.7%) |
| TB-500 | 10 mg | 9.796 mg | ✓ present | Within (-2%) |
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| BPC-157 | 5 mg | 4.921 mg | ✓ present | Within (-1.6%) |
| TB-500 | 5 mg | 5.167 mg | ✓ present | Within (+3.3%) |
Until more Wolverine vials are tested, the strongest signal is how each component performs in single-compound testing across the shops we track. Tap any card for its full data.
The Wolverine blend is a two-peptide research formulation combining BPC-157 and TB-500 in a 1:1 ratio, sold strictly for research use only. The name is also used loosely for a larger clinical protocol, so the first thing to verify is which one a vial actually is — and the per-component lab data above shows exactly what's inside.
The Wolverine blend is a two-peptide research vial combining BPC-157 and TB-500 (Thymosin Beta-4) in a 1:1 ratio, most commonly 10 mg or 20 mg total, sold for research use only. The name — borrowed from the comic-book character known for rapid healing — is a community label, not a clinical designation. One important disambiguation: some clinics use "Wolverine stack" for a four-peptide protocol that adds CJC-1295 and Ipamorelin to the base pair. The product sold as a single Wolverine vial is the two-peptide version.
The two components, and what each contributes:
| Component | Class & attributes | Role in the blend |
|---|---|---|
| BPC-157 | 15-amino-acid pentadecapeptide, MW 1419.5 Da | Local soft-tissue, tendon, and gut-lining repair |
| TB-500 (Thymosin β-4) | 43-amino-acid synthetic fragment of thymosin beta-4 | Cell migration, angiogenesis, systemic recovery |
The rationale for pairing them is that they act on non-overlapping parts of the same problem — BPC-157 primarily at the local injury site, TB-500 more systemically — which is why the combination anchors the tissue repair peptide category.
No controlled clinical trial of the BPC-157 + TB-500 combination has been published as of July 2026 — the pairing's rationale comes from single-compound research, most of it preclinical. BPC-157 is supported by more than 100 preclinical studies, predominantly from Prof. Predrag Sikirić's group at the University of Zagreb, starting with the 1993 foundational paper documenting tissue-protective effects; a 2025 orthopaedic systematic review found only one clinical study met inclusion criteria among 544 screened (evidence level: preclinical; no human RCTs). TB-500 (thymosin beta-4) has extensive preclinical wound-healing and cell-migration data and reached a first-in-human Phase 1 safety trial, but no efficacy RCT (evidence level: preclinical efficacy, Phase 1 safety only). Neither compound's human tissue-repair benefit has been confirmed in a controlled trial, individually or combined.
The component science is covered in the BPC-157 science guide and the TB-500 science guide.
Wolverine is the simplest of the tissue-repair blends: just BPC-157 and TB-500, with no third component. Adding GHK-Cu turns it into the GLOW blend (repair plus skin); adding GHK-Cu and KPV makes it KLOW. Choosing the two-peptide Wolverine over the separate single vials is a convenience-versus-control trade-off — a pre-blended 1:1 vial is drawn as one dose, while separate vials let BPC-157 and TB-500 run on independent schedules.
| Option | Components | Typical total | Vs. Wolverine |
|---|---|---|---|
| Wolverine | BPC-157 + TB-500 | 10–20 mg (1:1) | — |
| GLOW | GHK-Cu + BPC-157 + TB-500 | Varies (~10–70 mg) | Adds GHK-Cu |
| KLOW | GHK-Cu + BPC-157 + TB-500 + KPV | 80 mg | Adds GHK-Cu + KPV |
| Separate vials | BPC-157 and TB-500 apart | per vial | Independent dosing, no fixed ratio |
For the full side-by-side of the two peptides, see BPC-157 vs TB-500.
A Wolverine vial is worth verifying because even a two-peptide blend can be clean overall yet short one component. A certificate reports a single whole-vial HPLC purity — how clean the material is — but that number can read above 99% while one peptide is underdosed, so the verifiable signals are per-component: identity (mass spectrometry confirming both BPC-157 and TB-500 are present) and net content (tested milligrams versus label, for each). In a 1:1 blend, an imbalance is the quiet failure mode — a vial that delivers the BPC-157 it claims but half the TB-500 still "contains both." Peptigrity's independent lab-test database tracks both dimensions; learn to read them in how to read peptide lab test results.
Peptigrity verifies a Wolverine vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming both BPC-157 and TB-500 are present, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for each peptide), and endotoxin testing. Confirming the 1:1 balance is the point — the pairing only works as intended if both peptides are actually at label strength. Peptigrity purchases vials anonymously at standard pricing and publishes the unedited certificate; the methodology and shop trust-score weighting are documented in how we calculate trust scores. The broader process is in the how to test peptides hub and the testing labs directory. For sourcing each component, see where to buy BPC-157 and where to buy TB-500.
In a fixed 1:1 Wolverine vial you set the dose of one peptide and the other follows automatically, since both are present in equal amounts. A common research-planning approach reconstitutes a 20 mg vial (10 mg of each) and draws a single daily dose; the alternative is separate vials, dosing BPC-157 daily and TB-500 on a twice-weekly loading schedule. The dedicated BPC-157 + TB-500 calculator handles the blend math, and the Wolverine stack dosing guide walks through both formats. No clinical dosing protocol exists for the combination; every figure is community-derived from single-compound research, not a validated regimen.
Neither BPC-157 nor TB-500 is approved by the FDA or any other regulator for human use as of July 2026, and Wolverine is sold strictly as a research-use-only compound. In April 2026 the FDA removed both peptides from its 503A Category 2 bulk-substances list but did not add them to Category 1, leaving them in a regulatory gray zone — neither prohibited nor authorised for pharmacy compounding, with no FDA-approved product and no USP monograph. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review both on July 23–24, 2026, and the agency's pre-meeting briefing documents propose not adding them to the 503A Bulks List; these are advisory proposals, not final determinations. Both BPC-157 and TB-500 are prohibited by the World Anti-Doping Agency, so the Wolverine blend is banned in competitive sport.
In a blend you can only set the dose of one component — the rest follow the fixed ratio. Our calculator does that math so you don't underdose the peptide you actually care about.
Enter each component's milligrams and your BAC water — get per-component units for one syringe draw.
Open the blend calculator →How much bacteriostatic water, mixing without shaking, storage, and shelf life once mixed.
Read the reconstitution guide →The product sold as a single Wolverine vial is two peptides: BPC-157 and TB-500 in a 1:1 ratio. Separately, some clinics use "Wolverine stack" to describe a four-peptide protocol that adds CJC-1295 and Ipamorelin for growth-hormone support. They share a name but are different things — always check the label and certificate to confirm which combination a given vial contains.
The two are paired because they act on non-overlapping parts of tissue repair. BPC-157 works primarily at the local injury site — angiogenesis and tendon-to-bone healing in animal models — while TB-500 acts more systemically on cell migration and inflammation. The rationale is that together they cover more of the repair process than either alone, though no controlled trial has tested the combination in humans.
Yes, using two measurements. A lab reports a single whole-vial HPLC purity plus the net content of each peptide separately, with mass-spec identity confirmation. For a 1:1 blend this matters because the vial can be clean overall while one peptide is underdosed — so the per-component net content is what confirms both BPC-157 and TB-500 are actually at label strength.
Wolverine is generally sold as a research chemical for laboratory use, not as an approved drug, and it is not approved for human consumption anywhere as of July 2026. Legality of purchase for research use varies by jurisdiction, and buyers are responsible for verifying local import rules. Because it contains BPC-157 and TB-500, it is prohibited in competitive sport under WADA.
No. Peptigrity is an independent review platform, not a medical authority, and Wolverine is not approved for human use. No controlled trial has established a dose for the combination, and translating single-compound research into a self-administration protocol is a medical decision. Anyone considering use of investigational compounds should consult a licensed physician.